Pipeline

TRANSFORMING THE TREATMENT OF CARDIOVASCULAR DISEASE BY TARGETING CARDIAC ENERGY METABOLISM

We are conducting FORTITUDE-HCM (NCT07023614), a global, multicenter Phase 2b clinical trial to evaluate the efficacy and safety of ninerafaxstat in non-obstructive hypertrophic cardiomyopathy (nHCM).

 

Phase 2a clinical trials have been completed in non-obstructive hypertrophic cardiomyopathy (nHCM) and cardiometabolic syndromes, including heart failure with preserved ejection fraction (HFpEF).